Pfizer: Pre-clinical & Translational Research in Multiple Myeloma

Specific Area of Interest: 

The purpose of this RFP is to offer support to pre-clinical projects with a focus on these areas of interest:

• Correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRD-negativity, and response to prior therapy
• Understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS, OS) in the context of bispecific treatment
• Mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion)
• Correlation between Soluble BCMA and BCMA expression on myeloma cells (including assessment of gamma secretase activity)
• Impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels (including whether these prior treatments lead to BCMA mutations)
• Mechanistic understanding of the impact of anti-myeloma agents (e.g., IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity
• Exploring in-vitro or in-vivo novel combinations with elranatamab (PF-06863135) with a focus on drugs that are not currently SOC in myeloma
• Immunosuppressive mechanisms in the bone marrow that negatively impact bispecific (elranatamab) activity

Comparative analysis of bone marrow aspirate transcriptomes between responders and non-responders to elranatamab, and education to further the understanding of Cardiac Transthyretin Amyloid (ATTR).

Funding: up to $150,000.

https://cdn.pfizer.com/pfizercom/2021-07/GMG_2021-Oncology_Pre-clinicalTranslationalResearchMultipleMyeloma.pdf?UnRfpVUp54ppiJdAEQL4HUHwrLvuMhuY

https://www.pfizer.com/purpose/independent-grants/competitive-grants